|
RAPGEF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.79335999999086E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.167800E-04 |
| Normal-vs-Stage2 |
3.463600E-02 |
| Normal-vs-Stage3 |
2.36349999999108E-05 |
| Normal-vs-Stage4 |
3.09869999992607E-07 |
| Stage1-vs-Stage2 |
5.103200E-01 |
| Stage1-vs-Stage3 |
8.985700E-02 |
| Stage1-vs-Stage4 |
4.083400E-03 |
| Stage2-vs-Stage3 |
9.190400E-02 |
| Stage2-vs-Stage4 |
4.959300E-03 |
| Stage3-vs-Stage4 |
1.555960E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.54820000000311E-05 |
| Normal-vs-AfricanAmerican |
2.345800E-02 |
| Normal-vs-Asian |
7.575100E-04 |
| Caucasian-vs-AfricanAmerican |
7.380600E-01 |
| Caucasian-vs-Asian |
7.383800E-01 |
| AfricanAmerican-vs-Asian |
5.741000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.366600E-04 |
| Normal-vs-Female |
1.65760999999431E-05 |
| Male-vs-Female |
9.009000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.296400E-03 |
| Normal-vs-Age(41-60Yrs) |
6.37069999975814E-07 |
| Normal-vs-Age(61-80Yrs) |
9.78609999999769E-05 |
| Normal-vs-Age(81-100Yrs) |
9.713900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.723610E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.186350E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.054600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.942200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.886600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.556200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.397100E-03 |
| Classical-VS-Follicular |
1.333570E-01 |
| Classical-VS-Other |
9.102400E-02 |
| Classical-VS-Normal |
4.820300E-04 |
| Tall-VS-Follicular |
1.109170E-01 |
| Tall-VS-Other |
7.838600E-01 |
| Tall-VS-Normal |
1.69526999999059E-05 |
| Follicular-VS-Other |
2.714400E-01 |
| Follicular-VS-Normal |
1.797950E-04 |
| Other-VS-Normal |
6.981600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.013600E-04 |
| Normal-vs-N1 |
2.26199999997512E-06 |
| N0-vs-N1 |
1.838330E-02 |
|
|
